Krsnaa Diagnostics Ltd’s board, in a Monday filing, sanctioned the sale of identified freehold diagnostic equipment for an aggregate consideration of up to ₹120 cr—marking a deliberate shift toward a leaner asset profile.
The assets earmarked for divestiture are fully owned, carry no security interest for lenders, and are not part of the company’s collateral package, ensuring that the transaction does not erode its debt‑security framework.
Management emphasizes that the sale is an active portfolio optimisation exercise and not a response to impairment; it should leave the profit‑and‑loss statement untouched while potentially improving return on capital employed.
Market reaction was muted but negative: the stock closed at ₹536.65, down ₹11.80 or 2.15%, the steepest decline in the diagnostic services sector this week.
Looking ahead, Krsnaa intends to recycle the proceeds into core diagnostic operations and growth initiatives, with the board authorising the Operations Committee to finalise terms within the ₹120 cr ceiling. Analysts will watch for the impact on the company’s capital structure and any subsequent capital‑expenditure plans.